Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 27Myeloid 4Lymphoid 3Genitourinary 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Cyclophosphamide 886Rituximab 864Vincristine 382Etoposide 381fludarabine 342Cytarabine 341Doxorubicin 340fludarabine phosphate 319Methotrexate 310Dexamethasone 283Prednisone 281Lenalidomide 245Filgrastim 228Melphalan 200Peripheral Blood Stem Cell Transplantation 184Radiotherapy 175Whole-Body Irradiation 172Busulfan 165Mycophenolic Acid 161venetoclax 158Bendamustine Hydrochloride 158Granulocyte Colony-Stimulating Factor 151Tacrolimus 145ibrutinib 144Bortezomib 138obinutuzumab 125Gemcitabine 113Cyclosporine 110Antilymphocyte Serum 103Carmustine 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Homoharringtonine × Lymphoid × Clear all
NCT07159906 2025-09-08

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

First Affiliated Hospital of Zhejiang University

Phase 1/2 Not yet recruiting
62 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06855810 2025-08-26

CCCG-TALL-2025

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3 Recruiting
610 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06742463 2024-12-19

VHAG in Treating R/R T-ALL/LBL

First Affiliated Hospital of Zhejiang University

Phase 2 Recruiting
50 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡